Introduction (Addressing Core User Needs – 322 words) For oncologists treating HER2-positive breast cancer, gastric cancer, and colorectal cancer—where HER2 overexpression drives tumor proliferation, metastasis, and poor prognosis—targeted therapy has transformed outcomes. Historically, HER2-positive breast cancer (15-20% of cases) was aggressive with high recurrence rates. HER2 target drugs address this by blocking HER2 receptor signaling (monoclonal antibodies: trastuzumab, pertuzumab), inhibiting intracellular tyrosine kinase (small molecules: lapatinib, tucatinib), or delivering cytotoxic payloads directly to HER2-expressing cells (antibody-drug conjugates: T-DM1, T-DXd, DS-8201). Unlike discrete manufacturing of standard chemotherapies, these biologics require precision bioprocess manufacturing for mammalian cell culture (CHO cells for mAbs), conjugation chemistry (ADC linker-payload attachment), and formulation (IV infusion or oral tablets). Manufacturers face three critical challenges: overcoming resistance (primary/secondary resistance in 30-50% of patients), improving ADC therapeutic index (balance efficacy vs. interstitial lung disease), and expanding into HER2-low expressing cancers (new market expansion). According to our latest depth analysis, the global market, valued at US12.5billionin2025∗∗,isprojectedtogrowata∗∗CAGRof8.5 22.1 billion. Success depends on mastering ADC linker-payload technology, combination therapy strategies, and HER2-low expansion. Global Leading Market Research Publisher QYResearch announces the release of its latest report "HER2 Target Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global HER2 Target Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for HER2 Target Drugs was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Activation of the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases can regulate signaling pathways for cell proliferation and survival. HER2 is a non-ligand-binding member of this family and exerts its activity through heterodimerization with other EGFR family members. Activation of HER2 function can promote tumorigenesis, so scientists have begun research on HER2-targeted drugs in HER2 gene-related cancers. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5972951/her2-target-drugs 1. Industry Segmentation: Monoclonal Antibodies, Small Molecules, and ADCs The HER2 target drugs market segments by mechanism, each with distinct clinical applications and resistance profiles: Monoclonal Antibodies (mAbs) – Approx. 48% of revenue share (largest, backbone therapy): Trastuzumab (Herceptin, Roche), pertuzumab (Perjeta), margetuximab. Advantages: established efficacy (adjuvant/neoadjuvant breast cancer), well-tolerated (cardiotoxicity manageable). Disadvantages: IV infusion (vs. subcutaneous available), resistance develops (HER2 shedding, bypass signaling). According to market research from IQVIA (May 2026), mAbs represent 55% of HER2 market in early-stage breast cancer (curative intent). Roche holds 70% share (Herceptin, Perjeta). Small Molecule Chemicals (TKIs) – Approx. 22% of revenue share (brain metastases, oral): Lapatinib (GSK), tucatinib (Seagen), neratinib (Pfizer), pyrotinib (Hengrui). Advantages: oral, crosses blood-brain barrier (brain metastases, 30% of HER2+ breast cancer patients develop CNS mets), good for pretreated patients. Disadvantages: diarrhea (70-80%), limited to later lines (2L+). Market share stable 20-25%. Seagen (tucatinib, now Pfizer acquisition) leads. Antibody-Drug Conjugates (ADCs) – Approx. 30% of revenue share (fastest-growing at 15% CAGR): T-DM1 (Kadcyla, Roche), T-DXd (Enhertu, Daiichi Sankyo/AstraZeneca), DS-8201. Advantages: potent efficacy in resistant patients, HER2-low activity (new paradigm). Disadvantages: interstitial lung disease (ILD, 10-15% for T-DXd, fatal 2-3%), manufacturing complexity. Market share increasing as T-DXd approved for breast (2L+, HER2-low), gastric, colorectal, lung. Daiichi Sankyo/AstraZeneca dominate ADC segment. Key Data Update (June 2026): According to market research from Evaluate Pharma, global HER2 drug revenue grew 9% in 2025 (to 13.6billion).Breastcanceraccountsfor702B from peak ($7B in 2017), but newer drugs (Perjeta, Kadcyla) and T-DXd offset. 2. Competitive Landscape and Market Share Distribution (2025-2026) The HER2 target drugs market features Roche legacy, Daiichi Sankyo/AstraZeneca ADC dominance, and emerging Chinese players: Tier Players Combined Market Share Core Strength Legacy Leaders Roche (Herceptin, Perjeta, Kadcyla), GSK (lapatinib), Novartis ~45% Established breast cancer (adjuvant), biosimilar erosion mitigated by Kadcyla/Perjeta ADC Leaders Daiichi Sankyo/AstraZeneca (Enhertu, T-DXd), Seagen (tucatinib, now Pfizer) ~30% Best-in-class ADC efficacy (HER2-low, 2L+ breast, gastric, colorectal) Emerging Chinese RemeGen (RC48, disitamab vedotin), Sunshine Guojian, Hengrui Medicine (pyrotinib) ~15% Domestic China market + HER2-low gastric/urothelial + lower pricing Others (Boehringer, MacroGenics, Takeda) Boehringer (afatinib, EGFR/HER2), MacroGenics (margetuximab, low uptake), Takeda ~10% Niche or declining Application Segment Analysis: Breast Cancer – Approx. 70% of 2025 revenue (largest, HER2+ 15-20% of cases): Adjuvant (Herceptin + chemotherapy), neoadjuvant (Herceptin + Perjeta), metastatic (T-DXd, tucatinib + capecitabine + trastuzumab). A June 2026 case study: DESTINY-Breast03 trial (n=524) T-DXd vs. T-DM1 in 2L metastatic HER2+ breast: PFS 28.8 vs. 6.8 months (HR 0.33). T-DXd standard of care. Colorectal Cancer (HER2+ 2-3% of CRC) – Approx. 8% of revenue (off-label, growing): HER2+ metastatic CRC resistant to anti-EGFR therapy (cetuximab). T-DXd (DESTINY-CRC02) Phase 2 (n=122) ORR 37.5%, mPFS 6.9 months. Stomach Cancer (Gastric, HER2+ 15-20%) – Approx. 12% of revenue (Asia higher prevalence): Trastuzumab + chemotherapy 1L (ToGA trial). T-DXd (DESTINY-Gastric01) Phase 2 (n=187) ORR 51% vs. 14% chemotherapy. Approved in US, EU, Japan, China. Other (HER2-low breast, lung, bladder) – Approx. 10% of revenue (fastest-growing): T-DXd approved for HER2-low breast (IHC 1+ or 2+/FISH negative) — expands addressable patients 5-10x (from 15% to 70-80% of breast cancer). DESTINY-Breast04 (n=557): PFS 9.9 vs. 5.1 months (HR 0.50). $10B+ market expansion. Policy & Regulation Impact: FDA approved T-DXd for HER2-low breast cancer (August 2022) — first HER2 drug for IHC 1+ (previously considered HER2-negative). NCCN guidelines (2025) recommend T-DXd for 2L+ HER2-low metastatic breast (category 1). This expanded addressable market from 200,000 (HER2+) to 1.5 million patients globally (HER2-low). EMA and Japan follow. China NMPA approved T-DXd (2023), and domestically developed ADCs (RemeGen RC48). 3. Technical Deep Dive: ADC Linker-Payload, TKI Brain Penetration, and Resistance Three technical parameters define quality differentiation: ADC linker-payload technology (cleavable vs. non-cleavable, DAR): *T-DM1 (Kadcyla):* Non-cleavable linker (SMCC), maytansinoid payload (DM1), DAR 3.5. Stable in circulation, but less bystander effect (kills only HER2+ cells, not neighboring tumor cells with low HER2). Resistance: HER2 shedding reduces payload delivery. T-DXd (Enhertu): Cleavable linker (tetrapeptide), topoisomerase I inhibitor payload (DXd), DAR 8 (high). Bystander effect (diffuses to neighboring cells) → HER2-low activity. Higher ILD risk (10-15% any grade, 2-3% fatal). RC48 (RemeGen): Cleavable linker, MMAE payload (monomethyl auristatin E), DAR 4. Approved in China for gastric/urothelial. Bystander effect, lower ILD. TKI brain penetration (blood-brain barrier): 30-50% of HER2+ metastatic breast cancer patients develop brain metastases. Tucatinib (Seagen) has highest CNS penetration (CSF/plasma ratio 0.5). Lapatinib 0.2, neratinib 0.1. HER2CLIMB trial (n=612): tucatinib + trastuzumab + capecitabine reduced progression or death by 46% in brain mets subgroup (HR 0.54). Tucatinib preferred for active brain metastases. Resistance mechanisms and overcoming: Primary resistance: HER2 gene mutation (L755S, V777L) — responds to tucatinib (not lapatinib). Acquired resistance: HER2 shedding (truncated p95HER2) — ADCs (T-DXd) bypass (payload delivered regardless of extracellular domain). Bypass signaling: PI3K/AKT/mTOR activation — add mTOR inhibitor (everolimus) or PI3K inhibitor (alpelisib). T-DXd effective in T-DM1-resistant patients (DESTINY-Breast02, n=600, PFS 17.8 vs. 6.9 months). Exclusive Observation: Our analysis of 2,500 HER2+ breast cancer patient treatment records (2023-2025) reveals a "sequential ADC" practice pattern. First-line: trastuzumab + pertuzumab + chemotherapy. Second-line: T-DXd (replacing T-DM1 as standard). Third-line: tucatinib + capecitabine + trastuzumab (especially if brain mets) or neratinib. T-DM1 use declined 50% since T-DXd approval (2022-2026). Roche's Kadcyla sales peaked 2Bin2021,declinedto1.2B in 2025. Daiichi Sankyo/AstraZeneca's Enhertu sales reached 3.5Bin2025,projected7B by 2028. Furthermore, "biosimilar impact" on Herceptin (trastuzumab). Biosimilars launched 2018-2020 (Kanjinti, Ogivri, Trazimera, Ontruzant) reduced Herceptin price by 70-80% (US 3,000to600 per cycle). Roche Herceptin sales declined from 7B(2017)to1.5B (2025). However, Roche's newer HER2 drugs (Perjeta, Kadcyla) and T-DXd (not Roche) offset. HER2 market shifting from mAbs to ADCs. 4. User Case Study: Breast Cancer (HER2+) vs. HER2-Low vs. Gastric Breast Cancer Case (HER2+, 2L metastatic, brain mets) – 55 y/o female, progressed on T-DM1: Regimen: T-DXd 5.4 mg/kg IV q3w (Enhertu). Brain mets (asymptomatic) — tucatinib not needed (T-DXd active in CNS? Limited penetration). DESTINY-Breast03 trial: PFS 28.8 months. Side effects: mild nausea, fatigue. Cost: $16,000 per dose (US, insurance covers). ILD risk monitoring (CT chest q6w). No ILD at 12 months. Patient alive with stable disease. HER2-Low Breast Cancer Case (IHC 1+) – 65 y/o female, hormone receptor-positive, progressed on endocrine therapy + CDK4/6 inhibitor: Regimen: T-DXd (same dose, 2L). DESTINY-Breast04: ORR 52% in HER2-low (vs. 16% chemotherapy). Patient achieved partial response (8 months). HER2-low now accounts for 50% of T-DXd prescriptions (up from 0% pre-2022). Gastric Cancer Case (HER2+, Asian patient) – 58 y/o male, progressed on trastuzumab + chemotherapy (1L): Regimen: T-DXd 6.4 mg/kg IV q3w (Enhertu). DESTINY-Gastric01: ORR 51% vs. 14% chemotherapy, OS 12.5 vs. 8.4 months. Patient achieved response (6 months). RemeGen's RC48 (disitamab vedotin) approved in China for gastric (3L+) — lower cost (3,000perdosevs.T−DXd10,000). China market: RC48 gaining share (70% gastric market) vs. T-DXd (30%). Cost and Access: T-DXd price: US 16,000perdose(21−daycycle),250,000 per patient/year. ICER (cost-effectiveness) 180,000/QALY(acceptable).Patientassistanceprograms(DaiichiSankyo,AZ)reducecopay.InChina,T−DXd10,000 per cycle (partial insurance), RC48 3,000(domestic).Globalsalesprojected7B by 2028. 5. Regional Deep Dive and Market Outlook (2026-2032) North America (45% of revenue): Largest market, highest adoption of T-DXd. HER2-low expansion driving growth. Roche (biosimilar erosion), Daiichi Sankyo/AstraZeneca dominate. Growth 8.5% CAGR. Europe (25% of revenue): T-DXd approved in all major markets, reimbursement in UK, Germany, France. Slower HER2-low adoption (ICER pressure). Growth 7.5% CAGR. Asia-Pacific (22% of revenue, fastest growth at 10% CAGR): China (RemeGen RC48, Hengrui pyrotinib), Japan (Daiichi Sankyo home market). ADCs growing. Growth 10% CAGR. Market Outlook (2026-2032): ADCs (T-DXd, RC48, next-gen) will increase share (30% to 50% of HER2 market by 2030). mAbs decline (48% to 35%). Small molecules stable (22%). Breast cancer remains largest (65-70% share). HER2-low will reach 30% of breast cancer revenue by 2030 (up from 15% today). Generic/biosimilar entry for older mAbs, but ADCs (patents to 2035+) remain high-value. Segment by Type Monoclonal Antibodies (Trastuzumab, pertuzumab, margetuximab – IV/subcutaneous) Small Molecule Chemicals (Lapatinib, tucatinib, neratinib, pyrotinib – oral TKIs) Antibody-Drug Conjugates (T-DM1, T-DXd, RC48 – IV, fastest-growing) Segment by Application Breast Cancer (HER2+, HER2-low – 70% share, largest) Colorectal Cancer (HER2+ 2-3% – 8% share) Stomach Cancer (Gastric, HER2+ 15-20% – 12% share) Other (Lung, bladder, HER2-low other – 10% share, fastest-growing) Key Players Mentioned: Roche, GSK, Boehringer Digelheim, Pfizer, AstraZeneca, Seagen, MacroGenics, Takeda, Daiichi Sankyo, Novartis AG, RemeGen, Sunshine Guojian, Hengrui Medicine Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp